Drug Profile

MC 001

Alternative Names: MC-001- Medicovestor

Latest Information Update: 08 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medicovestor
Class Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity Yes

Highest Development Phases

Preclinical Pancreatic cancer

Most Recent Events

17 Jun 2025 MC 001 receives Orphan Drug status for Pancreatic cancer in USA
17 Jun 2025 Efficacy and adverse events data from preclinical studies in Pancreatic cancer released by Medicovestor (Medicovestor pipeline, June 2025)
10 Jun 2025 Preclinical trials in Pancreatic cancer in USA (Parenteral) before June 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com